Related Experiment Video
Updated: Oct 10, 2025

An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
In vivo antidiabetic potential of standardized Gymnocarpos decandrus Forssk. Extract
Seham S El-Hawary1, Mahmoud M Mubarek2, Rehab A Lotfy2
1Department of Pharmacognosy, Faculty of Pharmacy, Cairo University Kasr El-Ainy, Cairo, 11562 Egypt.
Background:
Gymnocarpos decandrus (Caryophyllaceae) is a well-known wild plant used as a food for grazing animals. Recently it showed potent antidiabetic potential beside its established anti-inflammatory, analgesic and diuretic activities. G. decandrus antidiabetic potential was reported through in-vitro models and resulted in promising α-amylase, α-glucosidase and antiviral Coxsackie B4 inhibitory activities; however no in-vivo studies were conducted.
Purpose:
This study aims to examine Gymnocarpos decandrus ethanol extract (GDEE) safety and to evaluate its in vivo antidiabetic potential.
Method:
Adult albino rats were injected intraperitoneally with alloxan to induce diabetes mellitus and the glucose level was measured after two and four weeks against metformin as a standard drug. Additionally, GDEE characterization and standardization were carried out.
Results:
GDEE LD50 was up to 5.8 mg/kg and exhibited significant antidiabetic activity 77.17% comparable to the standard drug metformin. Its total phenolics, and flavonoids amounted 127.2 ± 0.23 and 85.5 ± 0.21 mg/g respectively. Vitexin was used as a marker compound for GDEE (140.70 mg/100 gm).
Conclusion:
This study represents the sole in vivo scientific validation of G. decandrus recently documented in vitro antidiabetic potential.
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Oral Hypoglycemic Agents: Glinides
Oral Hypoglycemic Agents: Biguanides and Glitazones
Dipeptidyl Peptidase 4 Inhibitors
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...
Oral Hypoglycemic Agents: Sulfonylureas

